NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Tempest Therapeutics, Inc. (TPST) Stock Analysis

Tempest Therapeutics, Inc. (TPST) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TPST

$0.53

−$0.05 (−8.33%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TPST with… →

TPST Key Statistics

As of Oct 21, 2026
Trading
Open
$0.57
Previous Close
$0.58
Day's Range
0.52–0.62
52-Week Range
0.52–11.13
Volume
368.05K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.71
Valuation
Market Cap
$8.92M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.93
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$26.26M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
16.89M
1-Year Return
−94.98%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.58M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TPST closed at $0.53, −94.98% over 1 year.

Tempest Therapeutics, Inc. (TPST) has a market capitalization of $8.92M.

In fiscal 2025, TPST reported revenue of $0.00.

TPST Stock Return by Calendar Year

Tempest Therapeutics, Inc. (TPST) 10-year return: what $10,000 became

1 year
$10,000 $502
−94.98%
5 years
$10,000 $30
−99.70%
10 years
$10,000 $0.31
−99.997%

If you had invested $10,000 in Tempest Therapeutics, Inc. (TPST) 10 years ago, at the close on October 21, 2016, it would have been worth $0.31 at the close on October 21, 2026: −99.997% in total, −64.58% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−81.60%
2025−73.56%
2024−81.02%
2023+282.61%
2022−78.22%
2021−83.55%
2020−68.25%
2019−15.22%
2018−62.14%
2017−8.50%
2016 (partial year)−74.58%

As of October 21, 2026.

TPST Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.26M—
2024$0.00−$41.84M—
2023$0.00−$29.49M—
2022$0.00−$35.71M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$26.58M−$26.26M—
2024$0.00—−$42.03M−$41.84M—
2023$0.00—−$29.16M−$29.49M—
2022$0.00—−$34.64M−$35.71M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tempest Therapeutics, Inc. (TPST) carries a market capitalisation of $8.92M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 4.

The 52-week range on file runs from $0.52 to $11.13. The most recent close on file for TPST is $0.53, dated October 21, 2026. That is −$0.05 (−8.33%) against the previous close. The latest close sits 1.46% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $26.26M. Trailing earnings per share are −3.93.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at −1.71. Annualized volatility over the trailing 10 years is 1,262.35%. The trailing one-year total return is −94.98%. Measured over 10 years, that is −64.58% a year compounded.

Growth & Income

No dividend is on file for TPST.

2026 is still running; the total return is −81.60% year to date. Across the complete calendar years on file, 2023 returned +282.61% and 2021 returned −83.55%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

Tempest Therapeutics, Inc. (TPST) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tempest Therapeutics, Inc. TPST $8.92M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Tempest Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Visit website →